170 related articles for article (PubMed ID: 30715147)
21. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
22. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer.
Zhang J; Cai J; Bello A; Roy A; Sheng J
J Clin Pharmacol; 2019 Oct; 59(10):1415-1424. PubMed ID: 31115908
[TBL] [Abstract][Full Text] [Related]
23. Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
Leroy M; Desmedt E; Deramoudt L; Vasseur M; Odou P; Béhal H; Décaudin B; Mortier L; Simon N
Melanoma Res; 2024 Jun; 34(3):258-264. PubMed ID: 38489575
[TBL] [Abstract][Full Text] [Related]
24. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
25. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
26. An indirect comparison of long-term efficacy of every-2-week dosing vs. recommended dosing of ixekizumab in patients who had static Physician's Global Assessment > 1 at week 12.
Papp K; Maari C; Cauthen A; Gooderham M; Spelman L; Yamanaka K; Polzer P; Zhang L; Osuntokun O; Augustin M
Br J Dermatol; 2020 Jul; 183(1):52-59. PubMed ID: 31545506
[TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics and Exposure - Safety Analyses of Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma.
Wang X; Ludwig EA; Passarell J; Bello A; Roy A; Hruska MW
J Clin Pharmacol; 2019 Mar; 59(3):364-373. PubMed ID: 30339279
[TBL] [Abstract][Full Text] [Related]
28. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Waterhouse D; Horn L; Reynolds C; Spigel D; Chandler J; Mekhail T; Mohamed M; Creelan B; Blankstein KB; Nikolinakos P; McCleod MJ; Li A; Oukessou A; Agrawal S; Aanur N
Cancer Chemother Pharmacol; 2018 Apr; 81(4):679-686. PubMed ID: 29442139
[TBL] [Abstract][Full Text] [Related]
29. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
30. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of nivolumab four-weekly dosing schedule based on body weight.
de Lemos ML; Kung C; Waignein S
J Oncol Pharm Pract; 2019 Jun; 25(4):961-963. PubMed ID: 30808277
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
33. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
34. Dynamics of Acquired Resistance to Nivolumab Therapies Varies From Administration Strategies.
Ji J; Wu H; Feng X; Liu X; Huang C; Zheng S; Zou J; Liao J
Clin Ther; 2021 Dec; 43(12):2088-2103. PubMed ID: 34782163
[TBL] [Abstract][Full Text] [Related]
35. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
Peer CJ; Heiss BL; Goldstein DA; Goodell JC; Figg WD; Ratain MJ
J Clin Pharmacol; 2022 Apr; 62(4):532-540. PubMed ID: 34648187
[TBL] [Abstract][Full Text] [Related]
37. A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors.
Ma Y; Fang W; Zhang Y; Yang Y; Hong S; Zhao Y; Tendolkar A; Chen L; Xu D; Sheng J; Zhao H; Zhang L
Oncologist; 2019 Jul; 24(7):891-e431. PubMed ID: 31048330
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study.
Sureda M; Mata JJ; Catalán A; Escudero V; Martínez-Navarro E; Rebollo J
Farm Hosp; 2020 Apr; 44(3):81-86. PubMed ID: 32452306
[TBL] [Abstract][Full Text] [Related]
39. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.
Masters JC; Khandelwal A; di Pietro A; Dai H; Brar S
CPT Pharmacometrics Syst Pharmacol; 2022 Apr; 11(4):458-468. PubMed ID: 35166465
[TBL] [Abstract][Full Text] [Related]
40. Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
Liu SN; Lu T; Jin JY; Li C; Girish S; Melnikov F; Badovinac Crnjevic T; Machackova Z; Restuccia E; Kirschbrown WP
J Clin Pharmacol; 2021 Aug; 61(8):1096-1105. PubMed ID: 33719071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]